对HdxSim的推理,开发和验证,HdxSim是一个临床决策支持工具,用于在状细胞贫血儿童中以模型为基础精确剂量基尿素
Alexandra Power-Hays1,2,3, Min Dong2,4, Nieko Punt5
1Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Clinical pharmacology and therapeutics
|November 29, 2023
概括
基于模型的精确剂量 (MIPD) 的基尿素改善了患有状细胞贫血 (SCA) 的儿童的结果. 该HdxSim工具准确地预测了最佳的氧尿素剂量,使治疗在全球范围内更容易获得.
科学领域:
- 药理动力学和药理动力学
- 儿科血液学 儿科血液学
- 计算生物学 计算生物学
背景情况:
- 氧尿素是一种拯救生命的治疗方法,用于患有状细胞贫血 (SCA) 的儿童.
- 通过逐步升级到最大耐受剂量 (MTD) 来优化基尿素剂量具有挑战性,特别是在低收入环境中.
- 基于模型的精确剂量 (MIPD) 提供了一种更有效的方法来调整酸的剂量.
研究的目的:
- 开发和评估HdxSim,一个用户友好的,在线临床决策支持工具,用于氨酸MIPD.
- 评估HdxSim在估计基尿素暴露 (AUC) 和预测MTD使用真实世界药理动力学数据的准确性.
- 将HdxSim的性能与传统的药理动力学方法进行比较.
主要方法:
- HdxSim是为了促进酸MIPD而开发的.
- 分析了来自HUSTLE和TREAT临床试验的氧尿素第一剂药理学概况.
- HdxSim的AUC估计与传统的形方法和MWPharm-DOS软件进行了比较.
- 将HdxSim的预测剂量与观察到的临床MTD进行了比较.
主要成果:
- 与梯形法相比,HdxSim准确地估计了HUSTLE参与者的氨酸尿素AUC,差异<20%.
- 对于TREAT参与者,HdxSim的AUC估计略低于MWPharm-DOS (P=0.012),但推剂量没有显著差异 (P=0.97).
- 在预测临床MTD方面,HdxSim证明与MWPharm-DOS无劣 (P=0.19).
结论:
- HdxSim准确地估计了基尿素的暴露,并且与预测临床MTD的传统方法相比没有劣势.
- 以目标暴露为指导的基尿素剂量改善了SCA儿童的结果.
- HdxSim有可能提高SCA的药理学导向基尿素剂量的全球可用性.
相关概念视频
Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Dosage Regimen Designs: Nomograms and Tabulations
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
Dose Size and Dosing Frequency: Determination Methods
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


